AI-assisted ECG to speed diagnosis and treatment of occlusion heart attacks under a pay-for-performance program
Official title: A Randomized Clinical Trial Investigating the Impact of Artificial Intelligence Electrocardiography on Occlusion Myocardial Infarction Management Under the Value-Based Payment System
Run by National Defense Medical Center, Taiwan · NCT06887699 · Data updated 2026-11-12
This project will test whether adding an AI tool that flags ECGs for occlusion heart attacks and linking those alerts to a pay-for-performance program helps emergency department patients who get ECGs get diagnosed and treated faster and with better outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 212000 (estimated) |
| Sponsor | National Defense Medical Center, Taiwan Academic / other |
| Locations | 3 sites (Kaohsiung City, Taiwan and 2 other locations) |
| Status | Recruiting |
| Started | August 1, 2025 |
| Main results expected | March 31, 2028 |
| Study ends | June 30, 2028 |
| Registry record updated | April 9, 2026 |
| Trial ID | NCT06887699 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are emergency department patients at participating hospitals who receive at least one ECG and do not have a recent coronary angiography within the prior 3 days.
✕Probably not a fit
Patients who do not present to participating hospitals, do not receive an ECG, had ECGs while the AI system was inactive, or recently underwent coronary angiography are unlikely to benefit from the program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective interventional program integrates an AI-ECG algorithm into the hospital information system at three Taiwanese hospitals to generate real-time alerts when an ECG suggests occlusion myocardial infarction. Alerts are combined with a pay-for-performance (P4P) pathway that provides financial incentives to promote timely confirmation and reperfusion. The study enrolls emergency department patients who receive at least one ECG and compares diagnostic timeliness, treatment metrics, clinical outcomes, and healthcare costs associated with the AI-P4P pathway. Patients whose ECGs occurred while the AI was inactive or who had coronary angiography within the prior 3 days are excluded.
Why it matters
Potential benefit: If successful, this approach could lead to faster diagnosis and treatment of occlusion myocardial infarction, improving clinical outcomes and potentially lowering overall care costs.
How similar studies have gone: AI-ECG tools have shown promise in detecting acute coronary findings in prior work, but combining real-time AI ECG alerts with a pay-for-performance program for occlusion myocardial infarction is a novel approach that has not been widely tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients in the emergency department * Patients received at least 1 ECG examination. Exclusion Criteria: * The patients received ECG at the period of inactive AI-ECG system. * Patients with a history of coronary angiography within the past 3 days.
Where it's running
-
Kaohsiung Armed Forces General Hospital
Kaohsiung City, Taiwan, Taiwan Recruiting -
Taipei Municipal Wanfang Hospital
Taipei, Taiwan Recruiting -
Tri-Service General Hospital
Taipei, Taiwan Recruiting
Study contacts
- Principal investigator: Chin Lin, PhD — National Defense Medical Center
- Study coordinator: Chin Lin, PhD
- Email: xup6fup@mail.ndmctsgh.edu.tw
- Phone: +886-2-8792-3100
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-ECG alerts to catch early atrial fibrillation risk
This trial tests whether an AI-powered ECG alert can help doctors find people at high risk of developing atrial fibrillation so they can be given continuous heart-rhythm monitoring.
-
AI-assisted whole-course management for safe medicine use in advanced solid tumors
A real-world study compares a smartphone-based digital management system with usual care to see if it reduces drug-related problems and healthcare needs for adults with advanced solid tumors receiving cancer therapy.
-
Heart rate and respiration monitoring device: performance and usability in patients of all ages
We’re testing a new physiological monitor to see how well it works and how easy it is to use for patients from newborns to seniors.
-
AI-based cardiac analysis using 12-lead and 1-lead ECG
A clinician-facing pilot test to see if SmartECG-EF helps evaluate heart function using both 12-lead and single-lead ECGs in adults with heart conditions.
-
AI-assisted and traditional workflows for admission diagnosis and management planning
This trial tests whether an AI-agent workflow helps doctors make better admission diagnoses and care plans on simulated cases, compared with plain AI-assisted and traditional workflows.
-
Prediction score for death or lung transplant in emphysema caused by alpha-1 antitrypsin deficiency
This study tests a new prediction tool to identify people with emphysema due to alpha-1-antitrypsin deficiency who are at high risk of death or needing a lung transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.